Target intelligence / Profile preview

Schlafen family member 14 (SLFN14)

Target
SLFN14
Molecular classification
Enzyme (endoribonuclease/RNase), Nuclear protein, Helicase superfamily member (lacks ATPase activity), Schlafen protein family
01

Overview

Schlafen family member 14 (SLFN14) is an endoribonuclease and member of the Schlafen protein family implicated in RNA metabolism, immune defense, and human disease[1][2][3]. Structurally, SLFN14 consists of an RNase domain, a SWADL (Schlafen) domain, and a helicase-like C-terminal domain but lacks canonical helicase activity due to defective ATP binding[1]. SLFN14 binds and cleaves rRNA and ribosome-associated mRNAs, impacting protein translation[1][2][4]. Its normal function includes roles in the innate immune response and the development and secretion of platelets, explaining why mutations in SLFN14 cause inherited thrombocytopenia and bleeding disorders such as BDPLT20[1][2]. SLFN14 is also structurally related to other Schlafen proteins with important functions in cancer biology and immune defense, though its direct role as a therapeutic target is emerging primarily from genetic and structural studies rather than pharmacologic intervention[1][2][3][4].

Other names
Protein SLFN14C-terminally truncated SLFN14 endoribonucleaseSLFN14Schlafen family member 14BDPLT20
02

Biological functions

Endoribonucleolytic cleavage of RNA (including rRNA and tRNA)Innate immune response/antiviral defenseRegulation of protein translation (via ribosome interaction and mRNA/rRNA cleavage)Regulation of platelet function and megakaryopoiesis (platelet generation and secretion)
03

Disease associations

Inherited thrombocytopenia/platelet disorder (BDPLT20)Infection/antiviral responsepossible relevance in cancer (as inferred for Schlafen family members; specific SLFN14 cancer links are not fully established)
04

Safety considerations

Genetic variants associated with platelet dysfunction and bleeding risk (missense mutations in the RNase domain impair function)Potential concern: unintended suppression of global protein translation or immune dysregulation if broadly inhibited

Beyond the preview

Go deeper on Schlafen family member 14 (SLFN14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Schlafen family member 14 (SLFN14).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call